nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—prostate cancer—Dexamethasone—multiple sclerosis	0.267	0.387	CpDpCtD
Metoclopramide—prostate cancer—Betamethasone—multiple sclerosis	0.267	0.387	CpDpCtD
Metoclopramide—migraine—Prednisone—multiple sclerosis	0.155	0.225	CpDpCtD
Metoclopramide—CYP17A1—Dexamethasone—multiple sclerosis	0.101	0.716	CbGbCtD
Metoclopramide—CYP2D6—Fingolimod—multiple sclerosis	0.0322	0.228	CbGbCtD
Metoclopramide—HTR3A—area postrema—multiple sclerosis	0.0194	0.508	CbGeAlD
Metoclopramide—CYP2D6—Dexamethasone—multiple sclerosis	0.00785	0.0556	CbGbCtD
Metoclopramide—HTR3A—nerve—multiple sclerosis	0.00253	0.066	CbGeAlD
Metoclopramide—HTR4—brain—multiple sclerosis	0.00161	0.042	CbGeAlD
Metoclopramide—DRD2—nerve—multiple sclerosis	0.00155	0.0404	CbGeAlD
Metoclopramide—Sunitinib—MERTK—multiple sclerosis	0.0012	0.275	CrCbGaD
Metoclopramide—HTR3A—brainstem—multiple sclerosis	0.00109	0.0283	CbGeAlD
Metoclopramide—CYP17A1—medulla oblongata—multiple sclerosis	0.000965	0.0252	CbGeAlD
Metoclopramide—DRD3—nervous system—multiple sclerosis	0.000822	0.0215	CbGeAlD
Metoclopramide—Sunitinib—TYK2—multiple sclerosis	0.00081	0.186	CrCbGaD
Metoclopramide—DRD3—central nervous system—multiple sclerosis	0.000792	0.0207	CbGeAlD
Metoclopramide—CYP17A1—nervous system—multiple sclerosis	0.000725	0.0189	CbGeAlD
Metoclopramide—CYP17A1—central nervous system—multiple sclerosis	0.000698	0.0182	CbGeAlD
Metoclopramide—DRD2—brainstem—multiple sclerosis	0.000664	0.0173	CbGeAlD
Metoclopramide—DRD2—retina—multiple sclerosis	0.000641	0.0167	CbGeAlD
Metoclopramide—DRD3—brain—multiple sclerosis	0.000629	0.0164	CbGeAlD
Metoclopramide—HTR3A—nervous system—multiple sclerosis	0.000569	0.0149	CbGeAlD
Metoclopramide—Oxybuprocaine—BCHE—multiple sclerosis	0.000564	0.129	CrCbGaD
Metoclopramide—CYP17A1—brain—multiple sclerosis	0.000554	0.0145	CbGeAlD
Metoclopramide—HTR3A—central nervous system—multiple sclerosis	0.000548	0.0143	CbGeAlD
Metoclopramide—Chloroprocaine—BCHE—multiple sclerosis	0.000524	0.12	CrCbGaD
Metoclopramide—Procaine—BCHE—multiple sclerosis	0.0005	0.115	CrCbGaD
Metoclopramide—Cinchocaine—BCHE—multiple sclerosis	0.0005	0.115	CrCbGaD
Metoclopramide—HTR3A—brain—multiple sclerosis	0.000435	0.0114	CbGeAlD
Metoclopramide—CHRM1—nervous system—multiple sclerosis	0.000432	0.0113	CbGeAlD
Metoclopramide—DRD2—midbrain—multiple sclerosis	0.000423	0.0111	CbGeAlD
Metoclopramide—CHRM1—central nervous system—multiple sclerosis	0.000416	0.0109	CbGeAlD
Metoclopramide—CYP2D6—brainstem—multiple sclerosis	0.000399	0.0104	CbGeAlD
Metoclopramide—Mania—Prednisone—multiple sclerosis	0.000368	0.00679	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Mitoxantrone—multiple sclerosis	0.000359	0.00663	CcSEcCtD
Metoclopramide—Amenorrhoea—Dexamethasone—multiple sclerosis	0.00035	0.00645	CcSEcCtD
Metoclopramide—Amenorrhoea—Betamethasone—multiple sclerosis	0.00035	0.00645	CcSEcCtD
Metoclopramide—Fluid retention—Prednisolone—multiple sclerosis	0.00035	0.00645	CcSEcCtD
Metoclopramide—DRD2—nervous system—multiple sclerosis	0.000348	0.00909	CbGeAlD
Metoclopramide—DRD2—central nervous system—multiple sclerosis	0.000335	0.00875	CbGeAlD
Metoclopramide—CHRM1—brain—multiple sclerosis	0.00033	0.00862	CbGeAlD
Metoclopramide—Wheezing—Triamcinolone—multiple sclerosis	0.000329	0.00607	CcSEcCtD
Metoclopramide—DRD2—cerebellum—multiple sclerosis	0.000327	0.00855	CbGeAlD
Metoclopramide—Fluid retention—Triamcinolone—multiple sclerosis	0.000322	0.00593	CcSEcCtD
Metoclopramide—Fluid retention—Methylprednisolone—multiple sclerosis	0.000321	0.00592	CcSEcCtD
Metoclopramide—Delirium—Prednisone—multiple sclerosis	0.000311	0.00574	CcSEcCtD
Metoclopramide—Asthenia—Fingolimod—multiple sclerosis	0.000308	0.00569	CcSEcCtD
Metoclopramide—Amenorrhoea—Prednisone—multiple sclerosis	0.000305	0.00562	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Prednisolone—multiple sclerosis	0.000295	0.00544	CcSEcCtD
Metoclopramide—Diarrhoea—Fingolimod—multiple sclerosis	0.000294	0.00543	CcSEcCtD
Metoclopramide—Fluid retention—Dexamethasone—multiple sclerosis	0.000292	0.00538	CcSEcCtD
Metoclopramide—Fluid retention—Betamethasone—multiple sclerosis	0.000292	0.00538	CcSEcCtD
Metoclopramide—Agranulocytosis—Azathioprine—multiple sclerosis	0.00029	0.00535	CcSEcCtD
Metoclopramide—Hepatotoxicity—Methotrexate—multiple sclerosis	0.00029	0.00534	CcSEcCtD
Metoclopramide—Dizziness—Fingolimod—multiple sclerosis	0.000284	0.00524	CcSEcCtD
Metoclopramide—Visual disturbance—Prednisolone—multiple sclerosis	0.000282	0.0052	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Triamcinolone—multiple sclerosis	0.000271	0.005	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Methylprednisolone—multiple sclerosis	0.000271	0.00499	CcSEcCtD
Metoclopramide—Headache—Fingolimod—multiple sclerosis	0.000269	0.00497	CcSEcCtD
Metoclopramide—DRD2—brain—multiple sclerosis	0.000266	0.00694	CbGeAlD
Metoclopramide—Neutropenia—Mitoxantrone—multiple sclerosis	0.000263	0.00486	CcSEcCtD
Metoclopramide—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.000259	0.00479	CcSEcCtD
Metoclopramide—Procainamide—BCHE—multiple sclerosis	0.000259	0.0594	CrCbGaD
Metoclopramide—Cardiac arrest—Prednisolone—multiple sclerosis	0.000254	0.00469	CcSEcCtD
Metoclopramide—Fluid retention—Prednisone—multiple sclerosis	0.000254	0.00469	CcSEcCtD
Metoclopramide—Anxiety—Cladribine—multiple sclerosis	0.000253	0.00467	CcSEcCtD
Metoclopramide—Drowsiness—Mitoxantrone—multiple sclerosis	0.000251	0.00463	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Betamethasone—multiple sclerosis	0.000246	0.00454	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Dexamethasone—multiple sclerosis	0.000246	0.00454	CcSEcCtD
Metoclopramide—Confusional state—Cladribine—multiple sclerosis	0.000246	0.00453	CcSEcCtD
Metoclopramide—Jaundice—Mitoxantrone—multiple sclerosis	0.000245	0.00452	CcSEcCtD
Metoclopramide—Oedema—Cladribine—multiple sclerosis	0.000244	0.00449	CcSEcCtD
Metoclopramide—Tachycardia—Cladribine—multiple sclerosis	0.000238	0.00439	CcSEcCtD
Metoclopramide—Visual disturbance—Betamethasone—multiple sclerosis	0.000235	0.00434	CcSEcCtD
Metoclopramide—Visual disturbance—Dexamethasone—multiple sclerosis	0.000235	0.00434	CcSEcCtD
Metoclopramide—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.000234	0.00432	CcSEcCtD
Metoclopramide—Cardiac arrest—Triamcinolone—multiple sclerosis	0.000234	0.00431	CcSEcCtD
Metoclopramide—Cardiac arrest—Methylprednisolone—multiple sclerosis	0.000233	0.0043	CcSEcCtD
Metoclopramide—Bradycardia—Mitoxantrone—multiple sclerosis	0.00023	0.00423	CcSEcCtD
Metoclopramide—Respiratory failure—Methotrexate—multiple sclerosis	0.000228	0.0042	CcSEcCtD
Metoclopramide—Hypotension—Cladribine—multiple sclerosis	0.000228	0.0042	CcSEcCtD
Metoclopramide—Insomnia—Cladribine—multiple sclerosis	0.00022	0.00407	CcSEcCtD
Metoclopramide—Leukopenia—Azathioprine—multiple sclerosis	0.000217	0.00401	CcSEcCtD
Metoclopramide—Dyspnoea—Cladribine—multiple sclerosis	0.000217	0.00401	CcSEcCtD
Metoclopramide—Somnolence—Cladribine—multiple sclerosis	0.000217	0.004	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Prednisone—multiple sclerosis	0.000214	0.00395	CcSEcCtD
Metoclopramide—Asthma—Triamcinolone—multiple sclerosis	0.000213	0.00392	CcSEcCtD
Metoclopramide—Cardiac arrest—Dexamethasone—multiple sclerosis	0.000212	0.00391	CcSEcCtD
Metoclopramide—Cardiac arrest—Betamethasone—multiple sclerosis	0.000212	0.00391	CcSEcCtD
Metoclopramide—Fatigue—Cladribine—multiple sclerosis	0.00021	0.00388	CcSEcCtD
Metoclopramide—CYP2D6—nervous system—multiple sclerosis	0.000209	0.00546	CbGeAlD
Metoclopramide—Bronchospasm—Methylprednisolone—multiple sclerosis	0.000209	0.00385	CcSEcCtD
Metoclopramide—CYP2D6—central nervous system—multiple sclerosis	0.000201	0.00526	CbGeAlD
Metoclopramide—Feeling abnormal—Cladribine—multiple sclerosis	0.000201	0.0037	CcSEcCtD
Metoclopramide—Gynaecomastia—Methotrexate—multiple sclerosis	0.0002	0.00369	CcSEcCtD
Metoclopramide—CYP2D6—cerebellum—multiple sclerosis	0.000197	0.00514	CbGeAlD
Metoclopramide—Urticaria—Cladribine—multiple sclerosis	0.000194	0.00357	CcSEcCtD
Metoclopramide—Body temperature increased—Cladribine—multiple sclerosis	0.000193	0.00355	CcSEcCtD
Metoclopramide—Bradycardia—Prednisolone—multiple sclerosis	0.000188	0.00347	CcSEcCtD
Metoclopramide—Hypotension—Azathioprine—multiple sclerosis	0.000185	0.00342	CcSEcCtD
Metoclopramide—Cardiac arrest—Prednisone—multiple sclerosis	0.000185	0.00341	CcSEcCtD
Metoclopramide—Hypersensitivity—Cladribine—multiple sclerosis	0.00018	0.00331	CcSEcCtD
Metoclopramide—Visual impairment—Prednisolone—multiple sclerosis	0.000178	0.00329	CcSEcCtD
Metoclopramide—Leukopenia—Mitoxantrone—multiple sclerosis	0.000176	0.00324	CcSEcCtD
Metoclopramide—Asthenia—Cladribine—multiple sclerosis	0.000175	0.00323	CcSEcCtD
Metoclopramide—Bradycardia—Triamcinolone—multiple sclerosis	0.000173	0.00319	CcSEcCtD
Metoclopramide—Bradycardia—Methylprednisolone—multiple sclerosis	0.000173	0.00319	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—multiple sclerosis	0.000171	0.00316	CcSEcCtD
Metoclopramide—Convulsion—Mitoxantrone—multiple sclerosis	0.00017	0.00314	CcSEcCtD
Metoclopramide—Hypertension—Mitoxantrone—multiple sclerosis	0.000169	0.00313	CcSEcCtD
Metoclopramide—Hallucination—Methylprednisolone—multiple sclerosis	0.000169	0.00311	CcSEcCtD
Metoclopramide—Diarrhoea—Cladribine—multiple sclerosis	0.000167	0.00308	CcSEcCtD
Metoclopramide—Anxiety—Mitoxantrone—multiple sclerosis	0.000167	0.00307	CcSEcCtD
Metoclopramide—Visual impairment—Methylprednisolone—multiple sclerosis	0.000164	0.00302	CcSEcCtD
Metoclopramide—Feeling abnormal—Azathioprine—multiple sclerosis	0.000163	0.00301	CcSEcCtD
Metoclopramide—Confusional state—Mitoxantrone—multiple sclerosis	0.000162	0.00298	CcSEcCtD
Metoclopramide—Dizziness—Cladribine—multiple sclerosis	0.000161	0.00297	CcSEcCtD
Metoclopramide—Oedema—Mitoxantrone—multiple sclerosis	0.00016	0.00295	CcSEcCtD
Metoclopramide—CYP2D6—brain—multiple sclerosis	0.00016	0.00417	CbGeAlD
Metoclopramide—Bradycardia—Betamethasone—multiple sclerosis	0.000157	0.0029	CcSEcCtD
Metoclopramide—Bradycardia—Dexamethasone—multiple sclerosis	0.000157	0.0029	CcSEcCtD
Metoclopramide—Neutropenia—Prednisone—multiple sclerosis	0.000157	0.0029	CcSEcCtD
Metoclopramide—Body temperature increased—Azathioprine—multiple sclerosis	0.000157	0.00289	CcSEcCtD
Metoclopramide—Tachycardia—Mitoxantrone—multiple sclerosis	0.000156	0.00288	CcSEcCtD
Metoclopramide—Erectile dysfunction—Prednisone—multiple sclerosis	0.000155	0.00285	CcSEcCtD
Metoclopramide—Rash—Cladribine—multiple sclerosis	0.000154	0.00283	CcSEcCtD
Metoclopramide—Hallucination—Dexamethasone—multiple sclerosis	0.000154	0.00283	CcSEcCtD
Metoclopramide—Hallucination—Betamethasone—multiple sclerosis	0.000154	0.00283	CcSEcCtD
Metoclopramide—Dermatitis—Cladribine—multiple sclerosis	0.000154	0.00283	CcSEcCtD
Metoclopramide—Headache—Cladribine—multiple sclerosis	0.000153	0.00282	CcSEcCtD
Metoclopramide—Hypotension—Mitoxantrone—multiple sclerosis	0.00015	0.00276	CcSEcCtD
Metoclopramide—Depression—Prednisone—multiple sclerosis	0.000149	0.00275	CcSEcCtD
Metoclopramide—Visual impairment—Betamethasone—multiple sclerosis	0.000149	0.00274	CcSEcCtD
Metoclopramide—Visual impairment—Dexamethasone—multiple sclerosis	0.000149	0.00274	CcSEcCtD
Metoclopramide—Angioedema—Prednisolone—multiple sclerosis	0.000147	0.00271	CcSEcCtD
Metoclopramide—Hypersensitivity—Azathioprine—multiple sclerosis	0.000146	0.00269	CcSEcCtD
Metoclopramide—Nausea—Cladribine—multiple sclerosis	0.000145	0.00267	CcSEcCtD
Metoclopramide—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000143	0.00263	CcSEcCtD
Metoclopramide—Somnolence—Mitoxantrone—multiple sclerosis	0.000142	0.00263	CcSEcCtD
Metoclopramide—Asthma—Methotrexate—multiple sclerosis	0.00014	0.00259	CcSEcCtD
Metoclopramide—Convulsion—Prednisolone—multiple sclerosis	0.00014	0.00257	CcSEcCtD
Metoclopramide—Hypertension—Prednisolone—multiple sclerosis	0.000139	0.00256	CcSEcCtD
Metoclopramide—Fatigue—Mitoxantrone—multiple sclerosis	0.000138	0.00255	CcSEcCtD
Metoclopramide—Bradycardia—Prednisone—multiple sclerosis	0.000137	0.00252	CcSEcCtD
Metoclopramide—Diarrhoea—Azathioprine—multiple sclerosis	0.000136	0.0025	CcSEcCtD
Metoclopramide—Angioedema—Triamcinolone—multiple sclerosis	0.000135	0.0025	CcSEcCtD
Metoclopramide—Angioedema—Methylprednisolone—multiple sclerosis	0.000135	0.00249	CcSEcCtD
Metoclopramide—Hallucination—Prednisone—multiple sclerosis	0.000134	0.00247	CcSEcCtD
Metoclopramide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000132	0.00243	CcSEcCtD
Metoclopramide—Oedema—Prednisolone—multiple sclerosis	0.000131	0.00242	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—multiple sclerosis	0.000131	0.00242	CcSEcCtD
Metoclopramide—Dizziness—Azathioprine—multiple sclerosis	0.000131	0.00242	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000129	0.00238	CcSEcCtD
Metoclopramide—Convulsion—Triamcinolone—multiple sclerosis	0.000128	0.00237	CcSEcCtD
Metoclopramide—Tachycardia—Prednisolone—multiple sclerosis	0.000128	0.00237	CcSEcCtD
Metoclopramide—Convulsion—Methylprednisolone—multiple sclerosis	0.000128	0.00236	CcSEcCtD
Metoclopramide—Hypertension—Triamcinolone—multiple sclerosis	0.000128	0.00236	CcSEcCtD
Metoclopramide—Hypertension—Methylprednisolone—multiple sclerosis	0.000128	0.00235	CcSEcCtD
Metoclopramide—Urticaria—Mitoxantrone—multiple sclerosis	0.000127	0.00235	CcSEcCtD
Metoclopramide—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000127	0.00234	CcSEcCtD
Metoclopramide—Anxiety—Methylprednisolone—multiple sclerosis	0.000125	0.00231	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—multiple sclerosis	0.000125	0.00231	CcSEcCtD
Metoclopramide—Rash—Azathioprine—multiple sclerosis	0.000125	0.0023	CcSEcCtD
Metoclopramide—Dermatitis—Azathioprine—multiple sclerosis	0.000125	0.0023	CcSEcCtD
Metoclopramide—Depression—Methotrexate—multiple sclerosis	0.000125	0.0023	CcSEcCtD
Metoclopramide—Flushing—Prednisone—multiple sclerosis	0.000125	0.0023	CcSEcCtD
Metoclopramide—Headache—Azathioprine—multiple sclerosis	0.000124	0.00229	CcSEcCtD
Metoclopramide—Angioedema—Betamethasone—multiple sclerosis	0.000123	0.00226	CcSEcCtD
Metoclopramide—Angioedema—Dexamethasone—multiple sclerosis	0.000123	0.00226	CcSEcCtD
Metoclopramide—Confusional state—Methylprednisolone—multiple sclerosis	0.000122	0.00224	CcSEcCtD
Metoclopramide—Oedema—Triamcinolone—multiple sclerosis	0.000121	0.00223	CcSEcCtD
Metoclopramide—Insomnia—Prednisolone—multiple sclerosis	0.000119	0.00219	CcSEcCtD
Metoclopramide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000118	0.00218	CcSEcCtD
Metoclopramide—Tachycardia—Triamcinolone—multiple sclerosis	0.000118	0.00218	CcSEcCtD
Metoclopramide—Nausea—Azathioprine—multiple sclerosis	0.000118	0.00217	CcSEcCtD
Metoclopramide—Tachycardia—Methylprednisolone—multiple sclerosis	0.000118	0.00217	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000117	0.00215	CcSEcCtD
Metoclopramide—Convulsion—Dexamethasone—multiple sclerosis	0.000116	0.00215	CcSEcCtD
Metoclopramide—Convulsion—Betamethasone—multiple sclerosis	0.000116	0.00215	CcSEcCtD
Metoclopramide—Hypertension—Dexamethasone—multiple sclerosis	0.000116	0.00214	CcSEcCtD
Metoclopramide—Hypertension—Betamethasone—multiple sclerosis	0.000116	0.00214	CcSEcCtD
Metoclopramide—Asthenia—Mitoxantrone—multiple sclerosis	0.000115	0.00212	CcSEcCtD
Metoclopramide—Anxiety—Dexamethasone—multiple sclerosis	0.000114	0.0021	CcSEcCtD
Metoclopramide—Anxiety—Betamethasone—multiple sclerosis	0.000114	0.0021	CcSEcCtD
Metoclopramide—Hypotension—Methylprednisolone—multiple sclerosis	0.000113	0.00208	CcSEcCtD
Metoclopramide—Oedema—Dexamethasone—multiple sclerosis	0.00011	0.00202	CcSEcCtD
Metoclopramide—Oedema—Betamethasone—multiple sclerosis	0.00011	0.00202	CcSEcCtD
Metoclopramide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00011	0.00202	CcSEcCtD
Metoclopramide—Insomnia—Triamcinolone—multiple sclerosis	0.000109	0.00202	CcSEcCtD
Metoclopramide—Insomnia—Methylprednisolone—multiple sclerosis	0.000109	0.00201	CcSEcCtD
Metoclopramide—Feeling abnormal—Prednisolone—multiple sclerosis	0.000108	0.002	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—multiple sclerosis	0.000108	0.002	CcSEcCtD
Metoclopramide—Dyspnoea—Triamcinolone—multiple sclerosis	0.000108	0.00199	CcSEcCtD
Metoclopramide—Agitation—Prednisone—multiple sclerosis	0.000108	0.00198	CcSEcCtD
Metoclopramide—Tachycardia—Betamethasone—multiple sclerosis	0.000107	0.00197	CcSEcCtD
Metoclopramide—Tachycardia—Dexamethasone—multiple sclerosis	0.000107	0.00197	CcSEcCtD
Metoclopramide—Angioedema—Prednisone—multiple sclerosis	0.000107	0.00197	CcSEcCtD
Metoclopramide—Urticaria—Prednisolone—multiple sclerosis	0.000104	0.00193	CcSEcCtD
Metoclopramide—Fatigue—Triamcinolone—multiple sclerosis	0.000104	0.00192	CcSEcCtD
Metoclopramide—Fatigue—Methylprednisolone—multiple sclerosis	0.000104	0.00192	CcSEcCtD
Metoclopramide—Hypotension—Dexamethasone—multiple sclerosis	0.000102	0.00189	CcSEcCtD
Metoclopramide—Hypotension—Betamethasone—multiple sclerosis	0.000102	0.00189	CcSEcCtD
Metoclopramide—Convulsion—Prednisone—multiple sclerosis	0.000101	0.00187	CcSEcCtD
Metoclopramide—Hypertension—Prednisone—multiple sclerosis	0.000101	0.00186	CcSEcCtD
Metoclopramide—Rash—Mitoxantrone—multiple sclerosis	0.000101	0.00186	CcSEcCtD
Metoclopramide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000101	0.00186	CcSEcCtD
Metoclopramide—Headache—Mitoxantrone—multiple sclerosis	0.0001	0.00185	CcSEcCtD
Metoclopramide—Feeling abnormal—Triamcinolone—multiple sclerosis	9.96e-05	0.00184	CcSEcCtD
Metoclopramide—Feeling abnormal—Methylprednisolone—multiple sclerosis	9.94e-05	0.00183	CcSEcCtD
Metoclopramide—Anxiety—Prednisone—multiple sclerosis	9.93e-05	0.00183	CcSEcCtD
Metoclopramide—Insomnia—Betamethasone—multiple sclerosis	9.92e-05	0.00183	CcSEcCtD
Metoclopramide—Insomnia—Dexamethasone—multiple sclerosis	9.92e-05	0.00183	CcSEcCtD
Metoclopramide—Hypersensitivity—Prednisolone—multiple sclerosis	9.68e-05	0.00179	CcSEcCtD
Metoclopramide—Urticaria—Triamcinolone—multiple sclerosis	9.6e-05	0.00177	CcSEcCtD
Metoclopramide—Urticaria—Methylprednisolone—multiple sclerosis	9.58e-05	0.00177	CcSEcCtD
Metoclopramide—Body temperature increased—Triamcinolone—multiple sclerosis	9.55e-05	0.00176	CcSEcCtD
Metoclopramide—Oedema—Prednisone—multiple sclerosis	9.55e-05	0.00176	CcSEcCtD
Metoclopramide—Nausea—Mitoxantrone—multiple sclerosis	9.51e-05	0.00175	CcSEcCtD
Metoclopramide—Fatigue—Betamethasone—multiple sclerosis	9.45e-05	0.00174	CcSEcCtD
Metoclopramide—Fatigue—Dexamethasone—multiple sclerosis	9.45e-05	0.00174	CcSEcCtD
Metoclopramide—Tachycardia—Prednisone—multiple sclerosis	9.32e-05	0.00172	CcSEcCtD
Metoclopramide—Feeling abnormal—Dexamethasone—multiple sclerosis	9.04e-05	0.00167	CcSEcCtD
Metoclopramide—Feeling abnormal—Betamethasone—multiple sclerosis	9.04e-05	0.00167	CcSEcCtD
Metoclopramide—Hypersensitivity—Triamcinolone—multiple sclerosis	8.9e-05	0.00164	CcSEcCtD
Metoclopramide—Hypersensitivity—Methylprednisolone—multiple sclerosis	8.88e-05	0.00164	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—multiple sclerosis	8.75e-05	0.00161	CcSEcCtD
Metoclopramide—Urticaria—Dexamethasone—multiple sclerosis	8.71e-05	0.00161	CcSEcCtD
Metoclopramide—Urticaria—Betamethasone—multiple sclerosis	8.71e-05	0.00161	CcSEcCtD
Metoclopramide—Dizziness—Prednisolone—multiple sclerosis	8.69e-05	0.0016	CcSEcCtD
Metoclopramide—Asthenia—Triamcinolone—multiple sclerosis	8.67e-05	0.0016	CcSEcCtD
Metoclopramide—Body temperature increased—Dexamethasone—multiple sclerosis	8.67e-05	0.0016	CcSEcCtD
Metoclopramide—Body temperature increased—Betamethasone—multiple sclerosis	8.67e-05	0.0016	CcSEcCtD
Metoclopramide—Asthenia—Methylprednisolone—multiple sclerosis	8.65e-05	0.0016	CcSEcCtD
Metoclopramide—Insomnia—Prednisone—multiple sclerosis	8.64e-05	0.00159	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—multiple sclerosis	8.47e-05	0.00156	CcSEcCtD
Metoclopramide—Rash—Prednisolone—multiple sclerosis	8.29e-05	0.00153	CcSEcCtD
Metoclopramide—Dermatitis—Prednisolone—multiple sclerosis	8.28e-05	0.00153	CcSEcCtD
Metoclopramide—Diarrhoea—Methylprednisolone—multiple sclerosis	8.25e-05	0.00152	CcSEcCtD
Metoclopramide—Fatigue—Prednisone—multiple sclerosis	8.23e-05	0.00152	CcSEcCtD
Metoclopramide—Headache—Prednisolone—multiple sclerosis	8.23e-05	0.00152	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—multiple sclerosis	8.05e-05	0.00148	CcSEcCtD
Metoclopramide—Dizziness—Triamcinolone—multiple sclerosis	7.99e-05	0.00147	CcSEcCtD
Metoclopramide—Dizziness—Methylprednisolone—multiple sclerosis	7.97e-05	0.00147	CcSEcCtD
Metoclopramide—Feeling abnormal—Prednisone—multiple sclerosis	7.87e-05	0.00145	CcSEcCtD
Metoclopramide—Asthenia—Dexamethasone—multiple sclerosis	7.87e-05	0.00145	CcSEcCtD
Metoclopramide—Asthenia—Betamethasone—multiple sclerosis	7.87e-05	0.00145	CcSEcCtD
Metoclopramide—Nausea—Prednisolone—multiple sclerosis	7.81e-05	0.00144	CcSEcCtD
Metoclopramide—Rash—Triamcinolone—multiple sclerosis	7.62e-05	0.00141	CcSEcCtD
Metoclopramide—Dermatitis—Triamcinolone—multiple sclerosis	7.61e-05	0.0014	CcSEcCtD
Metoclopramide—Rash—Methylprednisolone—multiple sclerosis	7.6e-05	0.0014	CcSEcCtD
Metoclopramide—Dermatitis—Methylprednisolone—multiple sclerosis	7.6e-05	0.0014	CcSEcCtD
Metoclopramide—Urticaria—Prednisone—multiple sclerosis	7.59e-05	0.0014	CcSEcCtD
Metoclopramide—Headache—Triamcinolone—multiple sclerosis	7.57e-05	0.0014	CcSEcCtD
Metoclopramide—Headache—Methylprednisolone—multiple sclerosis	7.55e-05	0.00139	CcSEcCtD
Metoclopramide—Body temperature increased—Prednisone—multiple sclerosis	7.55e-05	0.00139	CcSEcCtD
Metoclopramide—Diarrhoea—Betamethasone—multiple sclerosis	7.5e-05	0.00138	CcSEcCtD
Metoclopramide—Diarrhoea—Dexamethasone—multiple sclerosis	7.5e-05	0.00138	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—multiple sclerosis	7.46e-05	0.00138	CcSEcCtD
Metoclopramide—Dizziness—Dexamethasone—multiple sclerosis	7.25e-05	0.00134	CcSEcCtD
Metoclopramide—Dizziness—Betamethasone—multiple sclerosis	7.25e-05	0.00134	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—multiple sclerosis	7.22e-05	0.00133	CcSEcCtD
Metoclopramide—Nausea—Triamcinolone—multiple sclerosis	7.18e-05	0.00132	CcSEcCtD
Metoclopramide—Nausea—Methylprednisolone—multiple sclerosis	7.16e-05	0.00132	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—multiple sclerosis	7.11e-05	0.00131	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—multiple sclerosis	7.09e-05	0.00131	CcSEcCtD
Metoclopramide—Hypersensitivity—Prednisone—multiple sclerosis	7.04e-05	0.0013	CcSEcCtD
Metoclopramide—Rash—Dexamethasone—multiple sclerosis	6.91e-05	0.00128	CcSEcCtD
Metoclopramide—Rash—Betamethasone—multiple sclerosis	6.91e-05	0.00128	CcSEcCtD
Metoclopramide—Dermatitis—Dexamethasone—multiple sclerosis	6.91e-05	0.00127	CcSEcCtD
Metoclopramide—Dermatitis—Betamethasone—multiple sclerosis	6.91e-05	0.00127	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—multiple sclerosis	6.88e-05	0.00127	CcSEcCtD
Metoclopramide—Headache—Betamethasone—multiple sclerosis	6.87e-05	0.00127	CcSEcCtD
Metoclopramide—Headache—Dexamethasone—multiple sclerosis	6.87e-05	0.00127	CcSEcCtD
Metoclopramide—Asthenia—Prednisone—multiple sclerosis	6.85e-05	0.00126	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—multiple sclerosis	6.58e-05	0.00121	CcSEcCtD
Metoclopramide—Diarrhoea—Prednisone—multiple sclerosis	6.53e-05	0.00121	CcSEcCtD
Metoclopramide—Nausea—Betamethasone—multiple sclerosis	6.51e-05	0.0012	CcSEcCtD
Metoclopramide—Nausea—Dexamethasone—multiple sclerosis	6.51e-05	0.0012	CcSEcCtD
Metoclopramide—Urticaria—Methotrexate—multiple sclerosis	6.34e-05	0.00117	CcSEcCtD
Metoclopramide—Dizziness—Prednisone—multiple sclerosis	6.31e-05	0.00116	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—multiple sclerosis	6.31e-05	0.00116	CcSEcCtD
Metoclopramide—Rash—Prednisone—multiple sclerosis	6.02e-05	0.00111	CcSEcCtD
Metoclopramide—Dermatitis—Prednisone—multiple sclerosis	6.02e-05	0.00111	CcSEcCtD
Metoclopramide—Headache—Prednisone—multiple sclerosis	5.98e-05	0.0011	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—multiple sclerosis	5.88e-05	0.00108	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—multiple sclerosis	5.73e-05	0.00106	CcSEcCtD
Metoclopramide—Nausea—Prednisone—multiple sclerosis	5.67e-05	0.00105	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—multiple sclerosis	5.46e-05	0.00101	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—multiple sclerosis	5.28e-05	0.000973	CcSEcCtD
Metoclopramide—Rash—Methotrexate—multiple sclerosis	5.03e-05	0.000928	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—multiple sclerosis	5.03e-05	0.000927	CcSEcCtD
Metoclopramide—Headache—Methotrexate—multiple sclerosis	5e-05	0.000922	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—multiple sclerosis	4.74e-05	0.000874	CcSEcCtD
Metoclopramide—CHRM1—GPCR downstream signaling—CCR1—multiple sclerosis	3.25e-05	0.000447	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GPR65—multiple sclerosis	3.22e-05	0.000444	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.2e-05	0.000441	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.2e-05	0.00044	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCR5—multiple sclerosis	3.19e-05	0.000438	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LINGO1—multiple sclerosis	3.19e-05	0.000438	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—S1PR1—multiple sclerosis	3.15e-05	0.000434	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—POMC—multiple sclerosis	3.15e-05	0.000433	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL10—multiple sclerosis	3.14e-05	0.000433	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.13e-05	0.000431	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LINGO1—multiple sclerosis	3.12e-05	0.000429	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—TYK2—multiple sclerosis	3.11e-05	0.000428	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—BCHE—multiple sclerosis	3.08e-05	0.000424	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL10—multiple sclerosis	3.08e-05	0.000423	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GPC5—multiple sclerosis	3.07e-05	0.000422	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.05e-05	0.00042	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL13—multiple sclerosis	3.01e-05	0.000415	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCR1—multiple sclerosis	3.01e-05	0.000415	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CD86—multiple sclerosis	2.98e-05	0.00041	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PTGER4—multiple sclerosis	2.97e-05	0.000409	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCR1—multiple sclerosis	2.95e-05	0.000406	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL13—multiple sclerosis	2.95e-05	0.000406	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	2.94e-05	0.000404	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL5—multiple sclerosis	2.94e-05	0.000404	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—BCHE—multiple sclerosis	2.88e-05	0.000397	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCR3—multiple sclerosis	2.87e-05	0.000395	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—IL2—multiple sclerosis	2.85e-05	0.000392	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL3—multiple sclerosis	2.81e-05	0.000386	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCR2—multiple sclerosis	2.79e-05	0.000384	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TAGAP—multiple sclerosis	2.76e-05	0.00038	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SPP1—multiple sclerosis	2.72e-05	0.000374	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL5—multiple sclerosis	2.71e-05	0.000372	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TAGAP—multiple sclerosis	2.7e-05	0.000372	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PTGER4—multiple sclerosis	2.7e-05	0.000372	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RGS1—multiple sclerosis	2.68e-05	0.000369	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL5—multiple sclerosis	2.65e-05	0.000364	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCR5—multiple sclerosis	2.64e-05	0.000364	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCR3—multiple sclerosis	2.61e-05	0.000359	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2RA—multiple sclerosis	2.61e-05	0.000359	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL2—multiple sclerosis	2.59e-05	0.000356	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CNR1—multiple sclerosis	2.58e-05	0.000355	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GPR65—multiple sclerosis	2.54e-05	0.00035	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SRM—multiple sclerosis	2.54e-05	0.00035	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCR2—multiple sclerosis	2.54e-05	0.000349	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	2.51e-05	0.000345	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.5e-05	0.000344	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—POMC—multiple sclerosis	2.49e-05	0.000343	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.45e-05	0.000337	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.45e-05	0.000337	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCR5—multiple sclerosis	2.44e-05	0.000335	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL2—multiple sclerosis	2.44e-05	0.000335	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—S1PR1—multiple sclerosis	2.41e-05	0.000332	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—APOE—multiple sclerosis	2.41e-05	0.000331	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.4e-05	0.00033	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCR5—multiple sclerosis	2.39e-05	0.000328	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—S1PR1—multiple sclerosis	2.36e-05	0.000325	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.36e-05	0.000324	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GPC5—multiple sclerosis	2.35e-05	0.000323	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CNR1—multiple sclerosis	2.34e-05	0.000322	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL13—multiple sclerosis	2.33e-05	0.00032	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCR1—multiple sclerosis	2.33e-05	0.00032	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL10—multiple sclerosis	2.32e-05	0.000319	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GPC5—multiple sclerosis	2.3e-05	0.000316	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PTGER4—multiple sclerosis	2.28e-05	0.000313	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.23e-05	0.000306	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCR3—multiple sclerosis	2.2e-05	0.000302	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CD80—multiple sclerosis	2.18e-05	0.000299	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—APOE—multiple sclerosis	2.15e-05	0.000296	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.15e-05	0.000296	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL3—multiple sclerosis	2.15e-05	0.000295	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCR2—multiple sclerosis	2.14e-05	0.000294	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL10—multiple sclerosis	2.11e-05	0.00029	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL3—multiple sclerosis	2.1e-05	0.000289	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCR2—multiple sclerosis	2.09e-05	0.000288	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—POMC—multiple sclerosis	2.07e-05	0.000284	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PTGER4—multiple sclerosis	2.07e-05	0.000284	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RGS1—multiple sclerosis	2.05e-05	0.000282	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—IL6—multiple sclerosis	2.02e-05	0.000279	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL2—multiple sclerosis	2.02e-05	0.000278	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PTGER4—multiple sclerosis	2.02e-05	0.000278	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RGS1—multiple sclerosis	2.01e-05	0.000276	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCL5—multiple sclerosis	2e-05	0.000275	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCR3—multiple sclerosis	2e-05	0.000275	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—MAPK1—multiple sclerosis	1.98e-05	0.000272	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CNR1—multiple sclerosis	1.97e-05	0.000272	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCR3—multiple sclerosis	1.95e-05	0.000269	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GPR65—multiple sclerosis	1.95e-05	0.000268	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCR2—multiple sclerosis	1.94e-05	0.000267	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CNR1—multiple sclerosis	1.93e-05	0.000266	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—POMC—multiple sclerosis	1.91e-05	0.000262	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GPR65—multiple sclerosis	1.9e-05	0.000262	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCR2—multiple sclerosis	1.9e-05	0.000261	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	1.87e-05	0.000257	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—POMC—multiple sclerosis	1.86e-05	0.000257	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL2—multiple sclerosis	1.86e-05	0.000257	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—APOE—multiple sclerosis	1.85e-05	0.000255	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—POMC—multiple sclerosis	1.85e-05	0.000254	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TYK2—multiple sclerosis	1.84e-05	0.000253	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL2—multiple sclerosis	1.82e-05	0.000251	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL5—multiple sclerosis	1.81e-05	0.00025	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCR5—multiple sclerosis	1.8e-05	0.000248	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CNR1—multiple sclerosis	1.79e-05	0.000247	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.79e-05	0.000246	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.79e-05	0.000246	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR1—multiple sclerosis	1.78e-05	0.000245	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL13—multiple sclerosis	1.78e-05	0.000245	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL10—multiple sclerosis	1.78e-05	0.000244	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2RA—multiple sclerosis	1.77e-05	0.000244	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CNR1—multiple sclerosis	1.75e-05	0.000241	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL13—multiple sclerosis	1.74e-05	0.00024	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR1—multiple sclerosis	1.74e-05	0.00024	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	1.74e-05	0.000239	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—APOE—multiple sclerosis	1.73e-05	0.000239	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ALB—multiple sclerosis	1.69e-05	0.000232	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL3—multiple sclerosis	1.66e-05	0.000228	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.64e-05	0.000225	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCR5—multiple sclerosis	1.63e-05	0.000225	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL10—multiple sclerosis	1.61e-05	0.000222	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2RA—multiple sclerosis	1.61e-05	0.000222	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTGER4—multiple sclerosis	1.6e-05	0.00022	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—POMC—multiple sclerosis	1.59e-05	0.000219	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL10—multiple sclerosis	1.58e-05	0.000217	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PGR—multiple sclerosis	1.57e-05	0.000216	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—multiple sclerosis	1.55e-05	0.000213	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCR3—multiple sclerosis	1.54e-05	0.000212	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCL5—multiple sclerosis	1.53e-05	0.00021	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2—multiple sclerosis	1.53e-05	0.00021	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CD28—multiple sclerosis	1.53e-05	0.00021	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—multiple sclerosis	1.52e-05	0.000209	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—multiple sclerosis	1.52e-05	0.000209	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCR2—multiple sclerosis	1.5e-05	0.000206	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCL5—multiple sclerosis	1.5e-05	0.000206	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—POMC—multiple sclerosis	1.49e-05	0.000205	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ALB—multiple sclerosis	1.45e-05	0.0002	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—multiple sclerosis	1.45e-05	0.000199	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.44e-05	0.000198	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—POMC—multiple sclerosis	1.41e-05	0.000194	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL5—multiple sclerosis	1.39e-05	0.000191	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CNR1—multiple sclerosis	1.38e-05	0.00019	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCR5—multiple sclerosis	1.38e-05	0.00019	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL5—multiple sclerosis	1.36e-05	0.000187	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ALB—multiple sclerosis	1.36e-05	0.000187	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2RA—multiple sclerosis	1.36e-05	0.000187	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.36e-05	0.000187	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCR5—multiple sclerosis	1.35e-05	0.000186	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.33e-05	0.000183	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—multiple sclerosis	1.29e-05	0.000177	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—POMC—multiple sclerosis	1.28e-05	0.000176	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL3—multiple sclerosis	1.27e-05	0.000175	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCR5—multiple sclerosis	1.25e-05	0.000172	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL2—multiple sclerosis	1.25e-05	0.000172	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL10—multiple sclerosis	1.25e-05	0.000171	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL3—multiple sclerosis	1.24e-05	0.000171	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2RA—multiple sclerosis	1.23e-05	0.00017	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCR5—multiple sclerosis	1.22e-05	0.000168	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTGER4—multiple sclerosis	1.22e-05	0.000168	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2RA—multiple sclerosis	1.21e-05	0.000166	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PGR—multiple sclerosis	1.2e-05	0.000165	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—multiple sclerosis	1.19e-05	0.000164	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTGER4—multiple sclerosis	1.19e-05	0.000164	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TGFB1—multiple sclerosis	1.19e-05	0.000164	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCR3—multiple sclerosis	1.18e-05	0.000162	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PGR—multiple sclerosis	1.18e-05	0.000162	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK1—multiple sclerosis	1.17e-05	0.000161	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CD28—multiple sclerosis	1.17e-05	0.000161	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCR3—multiple sclerosis	1.15e-05	0.000159	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR2—multiple sclerosis	1.15e-05	0.000158	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CD28—multiple sclerosis	1.14e-05	0.000157	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TYK2—multiple sclerosis	1.14e-05	0.000156	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR2—multiple sclerosis	1.12e-05	0.000154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CD86—multiple sclerosis	1.09e-05	0.00015	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—POMC—multiple sclerosis	1.08e-05	0.000148	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL5—multiple sclerosis	1.07e-05	0.000148	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CNR1—multiple sclerosis	1.06e-05	0.000146	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—POMC—multiple sclerosis	1.05e-05	0.000145	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—multiple sclerosis	1.04e-05	0.000143	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CNR1—multiple sclerosis	1.04e-05	0.000143	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SPP1—multiple sclerosis	9.93e-06	0.000137	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—POMC—multiple sclerosis	9.78e-06	0.000135	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCR5—multiple sclerosis	9.66e-06	0.000133	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—POMC—multiple sclerosis	9.57e-06	0.000132	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL2—multiple sclerosis	9.57e-06	0.000132	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL10—multiple sclerosis	9.53e-06	0.000131	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2RA—multiple sclerosis	9.52e-06	0.000131	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—multiple sclerosis	9.45e-06	0.00013	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL2—multiple sclerosis	9.36e-06	0.000129	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL10—multiple sclerosis	9.33e-06	0.000128	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—multiple sclerosis	8.98e-06	0.000124	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOE—multiple sclerosis	8.79e-06	0.000121	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	8.69e-06	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TYK2—multiple sclerosis	8.5e-06	0.000117	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CD86—multiple sclerosis	8.33e-06	0.000115	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL5—multiple sclerosis	8.2e-06	0.000113	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CD86—multiple sclerosis	8.16e-06	0.000112	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL5—multiple sclerosis	8.03e-06	0.00011	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	7.96e-06	0.00011	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CD80—multiple sclerosis	7.94e-06	0.000109	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—BCHE—multiple sclerosis	7.8e-06	0.000107	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—multiple sclerosis	7.79e-06	0.000107	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SPP1—multiple sclerosis	7.6e-06	0.000105	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—POMC—multiple sclerosis	7.55e-06	0.000104	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SPP1—multiple sclerosis	7.44e-06	0.000102	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR5—multiple sclerosis	7.39e-06	0.000102	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL2—multiple sclerosis	7.39e-06	0.000102	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	7.28e-06	0.0001	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR5—multiple sclerosis	7.23e-06	9.95e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—multiple sclerosis	7.23e-06	9.95e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK1—multiple sclerosis	7.23e-06	9.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2RA—multiple sclerosis	7.13e-06	9.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—multiple sclerosis	7.07e-06	9.73e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOE—multiple sclerosis	6.72e-06	9.25e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TYK2—multiple sclerosis	6.71e-06	9.23e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOE—multiple sclerosis	6.58e-06	9.05e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CD80—multiple sclerosis	6.08e-06	8.37e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CD80—multiple sclerosis	5.95e-06	8.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—POMC—multiple sclerosis	5.78e-06	7.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—POMC—multiple sclerosis	5.65e-06	7.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL2—multiple sclerosis	5.65e-06	7.78e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—multiple sclerosis	5.58e-06	7.68e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—multiple sclerosis	5.55e-06	7.64e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	5.53e-06	7.61e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	5.53e-06	7.61e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	5.41e-06	7.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—multiple sclerosis	5.28e-06	7.27e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TYK2—multiple sclerosis	5.13e-06	7.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	5.02e-06	6.91e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—multiple sclerosis	4.7e-06	6.46e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOE—multiple sclerosis	4.69e-06	6.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—multiple sclerosis	4.36e-06	6e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	4.35e-06	5.99e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—multiple sclerosis	4.27e-06	5.88e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	4.27e-06	5.87e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—multiple sclerosis	4.25e-06	5.85e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—multiple sclerosis	4.18e-06	5.75e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	4.16e-06	5.72e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—multiple sclerosis	4.04e-06	5.56e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—POMC—multiple sclerosis	4.03e-06	5.54e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	3.96e-06	5.44e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—multiple sclerosis	3.67e-06	5.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—multiple sclerosis	3.59e-06	4.94e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	3.52e-06	4.84e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—multiple sclerosis	3.34e-06	4.59e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	3.33e-06	4.58e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—multiple sclerosis	3.28e-06	4.51e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—multiple sclerosis	3.27e-06	4.5e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	3.27e-06	4.49e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	3.26e-06	4.49e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	3.2e-06	4.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—multiple sclerosis	2.51e-06	3.45e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—multiple sclerosis	2.46e-06	3.38e-05	CbGpPWpGaD
